Pfizer Stock up as Pfizer/Biontech and Moderna Updated Boosters Are Approved for Use in the US in Children as Young as 6 Months

Pfizer Stock

Pfizer‘s (NYSE:PFE), BioNTech’s (NASDAQ:BNTX), and Moderna’s (NASDAQ:MRNA) Omicron-adjusted COVID vaccines are now legal for use as boosters in children. These are young ones, some as young as six months old, according to a Thursday announcement from the FDA.

So, when the primary vaccine series is done, children between the ages of six months and five years will be able to get a single booster dose of the bivalent COVID-19 vaccines from Moderna (MRNA) and Pfizer (PFE)/BioNTech (BNTX).

The new booster doses, however, are not recommended for kids who have already finished the three-dose primary series with the original Pfizer (PFE)/BioNTech (BNTX) vaccine. The FDA says that in January, they will have the information they need to justify a second bivalent vaccination dose for this age range.

FDA Commissioner Robert Califf stressed the significance of being current on COVID vaccinations when announcing the choice as the holidays and winter months get near.

In August, the FDA approved the new COVID-19 booster shots, which were changed to work for the Omicron BA.4 and BA.5 subvariants of the virus.

Developments Behind Pfizer Stock

As a result, the FDA modified the emergency use authorizations (EUA) given to the vaccine makers. While the Pfizer/BioNTech (BNTX) vaccination is recommended for individuals over 12 years, the FDA has approved Moderna’s (NASDAQ:MRNA) vaccine for people over 18.

The monovalent booster shots made by businesses, which only work against the original strain of the virus, are no longer recommended for use as boosters for those over the age of 12, according to the FDA, which also noted that the latest permission.

As of November 30, according to government data, only 2.7% of eligible children under the age of two and less than 5% of those between the ages of two and four had finished their primary immunization series. This represents a delayed absorption of the initial vaccine doses in young children.

Featured Image – Pexels © Zoltán Bencze

Please See Disclaimer

About the author: I'm a financial freelance writer keen on the latest market developments which i articulate with writing stock updates, press releases and investor news. As a person i live by the code of a sustainable human existence and a carbon neutral universe. When off work, i spend time reading non-fiction books, flying drones, and outdoor cycling.